全文获取类型
收费全文 | 11853篇 |
免费 | 906篇 |
国内免费 | 75篇 |
专业分类
耳鼻咽喉 | 265篇 |
儿科学 | 704篇 |
妇产科学 | 105篇 |
基础医学 | 1058篇 |
口腔科学 | 153篇 |
临床医学 | 1110篇 |
内科学 | 3104篇 |
皮肤病学 | 252篇 |
神经病学 | 944篇 |
特种医学 | 593篇 |
外科学 | 1915篇 |
综合类 | 171篇 |
一般理论 | 3篇 |
预防医学 | 634篇 |
眼科学 | 319篇 |
药学 | 728篇 |
中国医学 | 16篇 |
肿瘤学 | 760篇 |
出版年
2023年 | 134篇 |
2022年 | 171篇 |
2021年 | 452篇 |
2020年 | 281篇 |
2019年 | 321篇 |
2018年 | 532篇 |
2017年 | 361篇 |
2016年 | 378篇 |
2015年 | 385篇 |
2014年 | 599篇 |
2013年 | 723篇 |
2012年 | 909篇 |
2011年 | 906篇 |
2010年 | 523篇 |
2009年 | 468篇 |
2008年 | 667篇 |
2007年 | 696篇 |
2006年 | 637篇 |
2005年 | 511篇 |
2004年 | 453篇 |
2003年 | 416篇 |
2002年 | 339篇 |
2001年 | 116篇 |
2000年 | 97篇 |
1999年 | 107篇 |
1998年 | 146篇 |
1997年 | 153篇 |
1996年 | 136篇 |
1995年 | 116篇 |
1994年 | 77篇 |
1993年 | 77篇 |
1992年 | 64篇 |
1991年 | 48篇 |
1990年 | 59篇 |
1989年 | 81篇 |
1988年 | 81篇 |
1987年 | 53篇 |
1986年 | 52篇 |
1985年 | 50篇 |
1984年 | 35篇 |
1983年 | 32篇 |
1982年 | 38篇 |
1981年 | 38篇 |
1980年 | 30篇 |
1979年 | 26篇 |
1978年 | 22篇 |
1977年 | 26篇 |
1976年 | 24篇 |
1972年 | 19篇 |
1971年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Sameer Arora Kamal Shemisa Muthiah Vaduganathan Arman Qamar Ankur Gupta Sushil K. Garg Dharam J. Kumbhani Helen Mayo Houman Khalili Ambarish Pandey Sandeep R. Das 《Journal of the American College of Cardiology》2019,73(19):2454-2464
Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor. 相似文献
4.
5.
6.
Sandeep Gohar Devendra Desai Anand Joshi Anita Bhaduri Ramesh Deshpande C Balkrishna Mukesh Chawla Camila Rodrigues V R Joshi 《Indian journal of gastroenterology》2003,22(4):140-142
INTRODUCTION: Autoimmune hepatitis (AIH) is a well-defined entity in the West but there are sparse Indian data on this disease. AIM: To study the clinical profile and response to treatment of Indian patients with AIH. METHODS: This is a part retrospective and part prospective study of 50 patients (median age 48 years, range 11-82; 43 women) seen between 1995 to 2001, diagnosed to have AIH as per the revised scoring system. Clinical and laboratory profile, response to treatment, and complications of treatment were analyzed. RESULTS: AIH accounted for 6% of all patients with liver disease seen during the period. The presenting symptoms were gastrointestinal in 43 and non-gastrointestinal in 7, with median symptom duration of 6 months (range 2 weeks to 40 years). Forty patients (80%) had chronic liver disease. Associated illnesses were present in 28 patients. Twenty-six patients were classified as definite and the rest as probable AIH. Forty-nine patients had Type 1 AIH. Five patients had overlap syndrome. Forty-five patients (90%) received immunosuppressive therapy. Twelve of 18 patients receiving only prednisolone and 21 of 27 patients receiving prednisolone and azathioprine combination responded. Thirteen (26%) patients had therapy-related complications (infectious 5, non infectious 8) with two treatment-related deaths. CONCLUSION: Type 1 AIH was the predominant type of AIH. The majority of patients with AIH presented with chronic liver disease. There was good response to immunosuppressive therapy. Therapy-related complications occurred in one-fourth of patients. 相似文献
7.
8.
Factors associated with the quality of laboratory performance in the United Kingdom external quality assessment scheme for serum growth hormone 总被引:1,自引:0,他引:1
J Seth I Hanning 《Clinica chimica acta; international journal of clinical chemistry》1988,174(2):185-195
A search was made for associations between poor performance in the UK External Quality Assessment Scheme (EQAS) for serum growth hormone (GH), and a range of factors including assay method, laboratory workload and staffing, and Internal Quality Control (IQC) procedures. On the basis of the factors identified as being associated with poor performance we recommend the following. 1. Laboratories using RIA for GH should routinely analyse samples at two dilutions and report a mean result. 2. The use of 125I-GH which is 5 or more weeks old should be avoided. Tracer should also be chromatographed to remove aggregate before use. 3. Laboratories using RIA should avoid using a standard curve which covers too wide a range concentration; a curve midpoint (ie GH concentration to reduce the zero standard binding by 50%) of about 8 mU/l or less is probably acceptable. 4. It should be noted that high workloads present a risk of some loss in quality of responsible for checking IQC data. 6. Laboratories which do not have the resources to maintain fully their own RIA as outlined above should carefully consider use of an unbiased, precise IRMA. The UK EQAS has identified two assays (Boots-Celltech Sucrosep, NETRIA) that appear to meet these criteria [2]. The above observations may also be relevant to immunoassays for other peptide hormones. 相似文献
9.
10.
Sandeep Mahajan Suresh C Tiwari Vikram Kalra Dipankar M Bhowmik Sanjay K Agarwal Suresh C Dash Parveen Kumar 《Peritoneal dialysis international》2005,25(5):473-477
BACKGROUND: Staphylococcus aureus-associated peritonitis and catheter exit-site infections (ESIs) are important causes of hospitalization and catheter loss in patients undergoing chronic peritoneal dialysis. Intranasal and topical use of mupirocin has been found to be an effective strategy in decreasing S. aureus-related infectious complications in persons who are carriers of S. aureus; however, there is no consensus regarding the prophylactic use of mupirocin irrespective of carrier status. We aimed to determine the potential effectiveness of application of mupirocin cream at the catheter exit site in preventing ESI and peritonitis irrespective of carrier status in a tropical country such as India. METHODS: This prospective historically controlled study was done in a total of 40 patients. From August 2003, all patients, incident and prevalent, were instructed to apply 2% mupirocin cream daily to the exit site instead of the older practice of povidone-iodine and gauze dressing. Patients were not screened to determine whether they were S. aureus carriers. The infection-related data for 1 year, until July 2004, were compared with the historical control, which was infection-related data for the year preceding the year of mupirocin application. RESULTS: Mean age of the study population was 62 years, with 61.8% being male and 64.3% being diabetic. Local application of mupirocin led to a significant reduction in the incidence density per patient-month of both ESI and peritonitis compared to controls (0.15 vs 0.37 and 0.37 vs 0.67, p = 0.01 for both). This amounted to a relative reduction of 60.5% and 55% respectively. ESI and peritonitis due to S. aureus were also significantly lower in the study group compared to controls (incidence density per patient-month 0.05 vs 0.13 and zero vs 0.17 respectively, p < 0.01 for both). There occurred no catheter removal due to infection-related complications during the study period compared to two during the control period. None of the patients reported a mupirocin-related adverse effect. CONCLUSIONS: Daily application of mupirocin at the exit site is a well-tolerated and effective strategy in reducing the incidence of ESI and peritonitis in a tropical country such as India. It can thus significantly reduce morbidity, catheter loss, and transfer to hemodialysis in peritoneal dialysis patients. 相似文献